[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.22643/JRMP.2018.4.1.32

Novel zirconium-89-based radiopharmaceuticals for medical application

Kim, Hee-Kwon (Department of Nuclear Medicine, Molecular Imaging & Therapeutic Medicine Research Center, Cyclotron Research Center, Biomedical Research Institute, Chonbuk National University Medical School and Hospital)

Publication Information

Journal of Radiopharmaceuticals and Molecular Probes / v.4, no.1, 2018 , pp. 32-35 More about this Journal

Abstract

Since utilization of metal is attractive research area applicable to medical applications, several metals have been studied by many scientists. Zr-89 is known as one of important radioisotopes nowadays. Novel ligands for Zr-89 have been developed, and Zr-89-based radiopharmaceuticals have been employed for positron emission tomography (PET) study. In this highlight review, recent advances on Zr-89 utilization for radiophramaceuticals are illustrated.

Keywords

Zr-89; Positron emission tomography (PET); Ligand;

Citations & Related Records

Reference

1	Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 2010;110:2858–2902. DOI
2	Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. $^{89}Zr-DFO-J591$ for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010;51:1293–1300. DOI
3	Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89.Nucl Med Biol 2009;36:729–739. DOI
4	Pandya DN, Bhatt N, Yuan H, Day CS, Ehrmann BM, Wright M, Bierbach U, Wadas TJ. Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chem Sci 2017;8:2309–2314. DOI
5	Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM. $^{89}Zr-huJ591$ immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2014;41:2093-2105. DOI
6	Ulaner GA, Hyman DM, Ross DS, Corben A, Chandarlapaty S, Goldfarb S, McArthur H, Erinjeri JP, Solomon SB, Kolb H, Lyashchenko SK, Lewis JS, Carrasquillo JA. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. J Nucl Med 2016;57:1523–1528. DOI
7	Gaykema SB, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, van Dam GM, van der Meulen SB, de Jong JR, Bart J, de Vries J, Jansen L, de Vries EG, Schroder CP. $^{89}Zr-bevacizumab$ PET imaging in primary breast cancer. J Nucl Med 2013;54:1014-1018. DOI
8	Gaykema SB, Schroder CP, Vitfell-Rasmussen J, Chua S, Oude Munnink TH, Brouwers AH, Bongaerts AH,Akimov M, Fernandez-Ibarra C, Lub-de Hooge MN, de Vries EG, Swanton C, Banerji U. $^{89}Zr-trastuzumab\;and\;^{89}Zr-bevacizumab$ PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Cancer Res 2014;20:3945–3954. DOI
9	Bahce I, Huisman MC, Verwer EE, Ooijevaar R, Boutkourt F, Vugts DJ, van Dongen GA, Boellaard R, Smit EF. Pilot study of $^{89}Zr-bevacizumab$ positron emission tomography in patients with advanced nonsmall cell lung cancer. EJNMMI Res 2014;4:35. DOI
10	Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, Hollema H, de Jong JR, de Jong IJ, de Haas S, Scherer SJ, Sluiter WJ, Dierckx RA, Bongaerts AH, Gietema JA, de Vries EG. $^{89}Zr-bevacizumab$ PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med 2015;56:63–69. DOI
11	van Asselt SJ, Oosting SF, Brouwers AH, Bongaerts AH, de Jong JR, Lub-de Hooge MN, Oude Munnink TH, Fiebrich HB, Sluiter WJ, Links TP, Walenkamp AM, de Vries EG. Everolimus reduces $^{89}Zr-bevacizumab$ tumor uptake in patients with neuroendocrine tumors. J Nucl Med 2014;55:1087–1092. DOI